Participated · Series A · Apr 2023

Abdera leverages its Radio Optimized Vector Engineering (ROVEr™) platform to design heavy‑chain‑only, antibody‑based radiopharmaceuticals engineered for optimal pharmacokinetics and radioisotope delivery. The company aims to improve therapeutic index by pairing engineered antibodies with alpha or beta emitting isotopes to selectively destroy tumor cells while sparing healthy tissue. Abdera’s lead program targets DLL3 for small cell lung cancer and other solid tumors and is advancing through preclinical development with an IND expected in 2024. The company says it has generated promising proof‑of‑concept data across tumor models and is building a pipeline against additional undisclosed cancer targets. Abdera is led by an experienced team spanning biologics, radiochemistry and oncology drug development. The company is based in Menlo Park, California and Vancouver, British Columbia.

Participated · Series A · Sep 2020

Invetx develops protein-based therapeutics for animal health, focusing on fully species-specific monoclonal antibodies for dogs and cats. The company has built an integrated discovery, development and manufacturing platform that generates optimized, half-life extended antibody candidates. It is advancing a broad pipeline across multiple therapeutic areas with several programs in pilot phase and a first product candidate currently in a clinical field study. Invetx plans to advance multiple candidates toward approval and expects product approvals potentially as early as 2025. The company has established collaborations with AbCellera, Twist Bioscience and Wuxi Biologics and a discovery, development and commercialization partnership with Boehringer Ingelheim. Financially, Invetx is well-capitalized following its recent financing and has raised $86 million since 2018 to support continued development and commercialization. Invetx develops protein- and antibody-based therapeutics and a novel discovery platform aimed at veterinary medicine. The company's platform is designed to address a wide range of indications and targets, including challenging targets such as G-protein-coupled receptors (GPCRs). Invetx is initially focused on diseases in dogs and cats and plans to apply its platform to other major veterinary species. The company completed a $25.5 million Series A financing in 2020. Invetx expects to begin pilot studies of its first development candidate in 2020. Recent executive hires and scientific advisors were announced to support antibody and veterinary biologics development. Invetx is building a biotechnology platform focused on protein-based therapeutics for animal health, including antibody medicines. The company aims to translate human biopharma technologies to veterinary applications and is developing a pipeline of recombinant protein therapies. Invetx plans to bring its first pet antibody therapeutic into clinical studies in 2020 and to advance substantial preclinical development across its pipeline. The company has established founding collaborations with WuXi Biologics for development and manufacturing and with AbCellera to accelerate antibody discovery. The $15 million Series A financing will support clinical entry of its lead candidate, expansion of the team, and continued preclinical programs. The global animal health market was estimated at $34 billion in 2019 with forecasted annual growth over six percent, which the company cites as driving demand for new therapeutics.